NCT04142437
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment with larotrectinib or other kinase inhibitor with TRK inhibition; Patients with NTRK gene amplification or NTRK point mutation
https://ClinicalTrials.gov/show/NCT04142437